Should We Treat Acute HIV Infection

作者: Meagan O’Brien , Martin Markowitz

DOI: 10.1007/S11904-012-0113-0

关键词:

摘要: Critical advances in the early diagnosis of HIV now allow for treatment opportunities during acute infection. It remains unclear whether infection with antiretroviral therapy improves long-term clinical outcomes individual and current guidelines are not definitive recommending at this stage However, may have short-term benefit on viral set point when compared to delayed as well reducing risk transmission others. Herein we review immunological literature discuss should treat infection, both from perspective HIV-infected patient public health perspective. As drug-resistant variants concern, also recent trial data provide recommendations which specific regimens be considered

参考文章(88)
Teresa Kauf, Mari Kitahata, Josephine Mauskopf, Anke Richter, Jerry Tolson, HIV antiretroviral treatment: early versus later. Journal of Acquired Immune Deficiency Syndromes. ,vol. 39, pp. 562- 569 ,(2005)
Fabio Franzetti, Claudia Balotta, Camilla Tincati, Mara Biasin, Luca Piacentini, Alessandra Bandera, Michela Violin, Giulia Marchetti, Andrea Gori, Mario Clerici, Mauro Moroni, Gian Luca Vago, Early initiation of highly active antiretroviral therapy fails to reverse immunovirological abnormalities in gut-associated lymphoid tissue induced by acute HIV infection. Antiviral Therapy. ,vol. 14, pp. 321- 330 ,(2009)
M Dorucci, G Rezza, D Vlahov, P Pezzotti, A Sinicco, A Nicolosi, A Lazzarin, N Galai, S Gafà, R Pristerà, Gioacchino Angarano, Clinical characteristics and prognostic value of acute retroviral syndrome among injecting drug users AIDS. ,vol. 9, pp. 597- 604 ,(1995) , 10.1097/00002030-199506000-00011
Strategies for Management of Antiretroviral Therapy (SMART) Study Group, None, CD4+ count-guided interruption of antiretroviral treatment. The New England Journal of Medicine. ,vol. 355, pp. 2283- 2296 ,(2006) , 10.1056/NEJMOA062360
Writing Committee for the CASCADE Collaboration, None, Timing of HAART Initiation and Clinical Outcomes in Human Immunodeficiency Virus Type 1 Seroconverters Archives of Internal Medicine. ,vol. 171, pp. 1560- 1569 ,(2011) , 10.1001/ARCHINTERNMED.2011.401
Class of antiretroviral drugs and the risk of myocardial infarction. The New England Journal of Medicine. ,vol. 356, pp. 1723- 1735 ,(2007) , 10.1056/NEJMOA062744
Eric S. Rosenberg, Marcus Altfeld, Samuel H. Poon, Mary N. Phillips, Barbara M. Wilkes, Robert L. Eldridge, Gregory K. Robbins, Richard T. D'Aquila, Philip J. R. Goulder, Bruce D. Walker, Immune control of HIV-1 after early treatment of acute infection Nature. ,vol. 407, pp. 523- 526 ,(2000) , 10.1038/35035103
Anita Shet, Leslie Berry, Hiroshi Mohri, Saurabh Mehandru, Chris Chung, Alexandria Kim, Patrick Jean-Pierre, Christine Hogan, Viviana Simon, Daniel Boden, Martin Markowitz, Tracking the prevalence of transmitted antiretroviral drug-resistant HIV-1: a decade of experience. Journal of Acquired Immune Deficiency Syndromes. ,vol. 41, pp. 439- 446 ,(2006) , 10.1097/01.QAI.0000219290.49152.6A
Suzanna Attia, Matthias Egger, Monika Müller, Marcel Zwahlen, Nicola Low, Sexual transmission of HIV according to viral load and antiretroviral therapy: systematic review and meta-analysis AIDS. ,vol. 23, pp. 1397- 1404 ,(2009) , 10.1097/QAD.0B013E32832B7DCA
Saurabh Mehandru, Michael A Poles, Klara Tenner-Racz, Patrick Jean-Pierre, Victoria Manuelli, Peter Lopez, Anita Shet, Andrea Low, Hiroshi Mohri, Daniel Boden, Paul Racz, Martin Markowitz, Lack of mucosal immune reconstitution during prolonged treatment of acute and early HIV-1 infection. PLOS Medicine. ,vol. 3, pp. 2335- 2348 ,(2006) , 10.1371/JOURNAL.PMED.0030484